Single cell protein profiling of focal cortical dysplasia in a patient requiring multiple resections

对一名需要多次切除的局灶性皮质发育不良患者进行单细胞蛋白质谱分析

阅读:2

Abstract

Epilepsy affects millions worldwide with many failing to respond to standard treatments. Drug-refractory epilepsy requiring surgical intervention often presents due to developmental aberrations, such as focal cortical dysplasia (FCD). In FCD type II, somatic mutations in the mTOR pathway allow excessive activation of the mTOR kinase, causing unregulated cell growth and differentiation. Ex vivo studies of resected brain tissues offer a direct window into epileptogenic brain and disease pathophysiology. Recent studies implicate abnormal cell fate specification in FCD, but it is unclear if mutant cells are directly epileptogenic and/or whether they impact neighboring cells. Using a custom 43-antibody mass cytometry panel, we broadly assessed cell lineage and functional state across multiple sequential resections from a female child with FCD harboring a mosaic gain-of-function AKT3 mutation. Our approach used unsupervised machine learning tools to define protein-level features of dysplasia-associated cells and revealed cell populations associated with clinical outcomes. While AKT3 mutational burden did not correlate with clinical outcomes, protein profiling identified a distinct population of CUX1-high cells correlating with seizure control. Furthermore, we identified a similar cell population across multiple additional cortical malformation cases. This work demonstrates the advantage of deep single-cell protein profiling of surgically resected epilepsy tissue and provides insight on disease mechanisms that can be overlooked in traditional genetic or transcriptional studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-026-02273-3.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。